1Pfisterer M,Brunner-La Rocca HP,Buser PT,et al.Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:an observational study of drug-eluting versus bare-metal stents.J Am Coll Cardiol,2006,48:2584-2591.
2Yamashita A,Sumi T,Goto S,et al.Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction.Am J Cardiol,2006,97:26-28.
3Groebke Zbinden K,Banner DW,Ackermann J,et al.Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors.Bioorg Med Chem Lett,2005,15:817-822.
4Stampfuss JJ,Censarek P,Fischer JW,et al.Rapid release of active tissue factor from human arterial smooth muscle cells under flow conditions.Arterioscler Thromb Vasc Biol,2006,26:34-37.
5Day SM,Reeve JL,Pedersen B,et al.Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall.Blood,2005,105:192-198.
6Siddiqui FA,Desai H,Amirkhosravi A,et al.The p resence and release of tissue factor from human platelets.Platelets,2002,13:247-253.
7Ghrib F,Brisset AC,Dupouy D,et al.The expression of tissue factor and tissue factor pathway inhibitor in aortic smooth muscle cells is up-2regulated in synthetic compared to contractile phenotype.Thromb Haemost,2002,87:1051-1056.
8Maly MA,Tomasov P,Hájek P,et al.The role of tissue factor in thrombosis and hemostasis.Physiol Res,2007,56:685-695.
9Chung NA,Lydakis C,Belgore F,et al.Angiogenesis,thrombogenesis,endothelial dysfunction and angiographic severity of coronary artery disease.Heart,2003,89:1411-1415.
10Meerarani P,Moreno PR,Cimmino G,et al.Atherothrombosis:role of tissue factor,link between diabetes,obesity and inflammation.Indian J Exp Biol,2007,45:103-110.
同被引文献7
1Navarese EP, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP- antagonist regimens in acute coronary syndromes: a meta-analy- sis of randomized trials. QJM, 2011,104 : 561-569.
2Frelinger AL 3rd, Michelson AD, Wiviott SD, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasug- rel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost, 2011,106 : 219-226.
3Jung JH, Min PK, Lee SH, et al. Clopidogrel pretreatment be- fore primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 rag) versus low loading dose (300 mg). Coron Artery Dis, 2009,20 : 150-154.
4Levine GN, Bates ERr Blankenship JC, et al. 2011 ACCF/AHA/ SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foun- dation/American Heart Association Task Force on Practice Guide- lines and the Society for Cardiovascular Angiography and Inter- ventions. Catheter Cardiovasc Interv, 2012,79 : 453-495.
5Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J, 2010,31 : 2501-2555.
6Price M J, Berger PB, Teirstein PS, et al. Standard- vs high- dose clopidogrel based on platelet function testing after percuta- neous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011,305 : 1097-1105.
7Bonello L, Berbis J, Laine M, et al. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarc- tion. Thromb I-Iaemost, 2012,108 : 101-106.
